Abstract
7520 Background: Adjuvant chemotherapy (CT) improves overall survival (OS) in patients with completely resected stage II and III non-small cell lung cancer (NSCLC). However, its role in patients with stage IB disease remains unclear. We therefore evaluated the role of adjuvant CT in patients with completely resected T2N0M0 NSCLC. Methods: Patients with pathologic stage T2N0M0 NSCLC who underwent complete (R0) resection from 2003 to 2010 were identified from the National Cancer Database (NCDB). Patients were grouped based on tumor size: 3-3.9 cm, 4-4.9 cm, 5-5.9 cm and 6-7 cm. Survival curves according to the CT status were estimated by the Kaplan-Meier product-limit method and compared by log-rank test. Cox proportional hazard model was used to evaluate whether adjuvant CT was an independent predictor for survival for each tumor size groups. Results: Among the 29,908 patients meeting inclusion criteria, there were 5,209 (17.4%) and 24,699 (82.6%) patients in the CT and observation groups respectively. Pat...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
